Abstract

Microvesicles (MVs) are subcellular physiological vehicles present in all body fluids that mediate the transfer of intercellular information within biological systems and contribute to healthy conditions. MVs have lipid bilayer membranes decorated with multiple ligands that can interact with receptors on target cells, rendering them as promising candidates for targeted delivery. The biotechnology and cell therapy industries are developing MV-based preparations that use this subcellular therapeutic machinery (in a naïve or modified state) for regenerative medicine, as substitutes for intact cell therapy, and as intelligent targeted drug delivery carriers. However, significant production challenges must be overcome before MVs scale-up development, clinical translation, and routine therapeutic application can be realized. The unique expertise developed in the biotechnology industry should facilitate market access to MV-based therapeutics. In this review, the roles of biotechnology and cell therapy industries to manufacture MVs as inherent therapeutic agents or drug delivery systems are summarized. The manufacturing, development, characterization, and regulatory challenges for successful translation are discussed.

Original languageEnglish
JournalTrends in Biotechnology
DOIs
Publication statusAccepted/In press - Jan 1 2019

Fingerprint

Biotechnology
Cell- and Tissue-Based Therapy
Industry
State Medicine
Drug Carriers
Lipid bilayers
Regenerative Medicine
Body fluids
Lipid Bilayers
Body Fluids
Therapeutic Uses
Biological systems
Drug Delivery Systems
Membrane Lipids
Machinery
Therapeutics
Ligands
Membranes

Keywords

  • assessment
  • clinical translation
  • clinical use
  • delivery systems
  • extracellular vesicles
  • functions
  • isolation
  • microvesicles
  • purification
  • therapies
  • tissue regeneration

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering

Cite this

Extracellular Microvesicles as New Industrial Therapeutic Frontiers. / Agrahari, Vivek; Agrahari, Vibhuti; Burnouf, Pierre Alain; Chew, Chee Ho; Burnouf, Thierry.

In: Trends in Biotechnology, 01.01.2019.

Research output: Contribution to journalArticle

Agrahari, Vivek ; Agrahari, Vibhuti ; Burnouf, Pierre Alain ; Chew, Chee Ho ; Burnouf, Thierry. / Extracellular Microvesicles as New Industrial Therapeutic Frontiers. In: Trends in Biotechnology. 2019.
@article{4b2c188b830b49a7bbb24291795803c0,
title = "Extracellular Microvesicles as New Industrial Therapeutic Frontiers",
abstract = "Microvesicles (MVs) are subcellular physiological vehicles present in all body fluids that mediate the transfer of intercellular information within biological systems and contribute to healthy conditions. MVs have lipid bilayer membranes decorated with multiple ligands that can interact with receptors on target cells, rendering them as promising candidates for targeted delivery. The biotechnology and cell therapy industries are developing MV-based preparations that use this subcellular therapeutic machinery (in a na{\"i}ve or modified state) for regenerative medicine, as substitutes for intact cell therapy, and as intelligent targeted drug delivery carriers. However, significant production challenges must be overcome before MVs scale-up development, clinical translation, and routine therapeutic application can be realized. The unique expertise developed in the biotechnology industry should facilitate market access to MV-based therapeutics. In this review, the roles of biotechnology and cell therapy industries to manufacture MVs as inherent therapeutic agents or drug delivery systems are summarized. The manufacturing, development, characterization, and regulatory challenges for successful translation are discussed.",
keywords = "assessment, clinical translation, clinical use, delivery systems, extracellular vesicles, functions, isolation, microvesicles, purification, therapies, tissue regeneration",
author = "Vivek Agrahari and Vibhuti Agrahari and Burnouf, {Pierre Alain} and Chew, {Chee Ho} and Thierry Burnouf",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.tibtech.2018.11.012",
language = "English",
journal = "Trends in Biotechnology",
issn = "0167-7799",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Extracellular Microvesicles as New Industrial Therapeutic Frontiers

AU - Agrahari, Vivek

AU - Agrahari, Vibhuti

AU - Burnouf, Pierre Alain

AU - Chew, Chee Ho

AU - Burnouf, Thierry

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Microvesicles (MVs) are subcellular physiological vehicles present in all body fluids that mediate the transfer of intercellular information within biological systems and contribute to healthy conditions. MVs have lipid bilayer membranes decorated with multiple ligands that can interact with receptors on target cells, rendering them as promising candidates for targeted delivery. The biotechnology and cell therapy industries are developing MV-based preparations that use this subcellular therapeutic machinery (in a naïve or modified state) for regenerative medicine, as substitutes for intact cell therapy, and as intelligent targeted drug delivery carriers. However, significant production challenges must be overcome before MVs scale-up development, clinical translation, and routine therapeutic application can be realized. The unique expertise developed in the biotechnology industry should facilitate market access to MV-based therapeutics. In this review, the roles of biotechnology and cell therapy industries to manufacture MVs as inherent therapeutic agents or drug delivery systems are summarized. The manufacturing, development, characterization, and regulatory challenges for successful translation are discussed.

AB - Microvesicles (MVs) are subcellular physiological vehicles present in all body fluids that mediate the transfer of intercellular information within biological systems and contribute to healthy conditions. MVs have lipid bilayer membranes decorated with multiple ligands that can interact with receptors on target cells, rendering them as promising candidates for targeted delivery. The biotechnology and cell therapy industries are developing MV-based preparations that use this subcellular therapeutic machinery (in a naïve or modified state) for regenerative medicine, as substitutes for intact cell therapy, and as intelligent targeted drug delivery carriers. However, significant production challenges must be overcome before MVs scale-up development, clinical translation, and routine therapeutic application can be realized. The unique expertise developed in the biotechnology industry should facilitate market access to MV-based therapeutics. In this review, the roles of biotechnology and cell therapy industries to manufacture MVs as inherent therapeutic agents or drug delivery systems are summarized. The manufacturing, development, characterization, and regulatory challenges for successful translation are discussed.

KW - assessment

KW - clinical translation

KW - clinical use

KW - delivery systems

KW - extracellular vesicles

KW - functions

KW - isolation

KW - microvesicles

KW - purification

KW - therapies

KW - tissue regeneration

UR - http://www.scopus.com/inward/record.url?scp=85059642047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059642047&partnerID=8YFLogxK

U2 - 10.1016/j.tibtech.2018.11.012

DO - 10.1016/j.tibtech.2018.11.012

M3 - Article

AN - SCOPUS:85059642047

JO - Trends in Biotechnology

JF - Trends in Biotechnology

SN - 0167-7799

ER -